about
Incidence of unanticipated difficult airway using an objective airway score versus a standard clinical airway assessment: the DIFFICAIR trial - trial protocol for a cluster randomized clinical trialComparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationalSulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysisHydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysisViewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviewsAntithrombin III for critically ill patientsProthrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patientsNon-invasive positive pressure ventilation for acute asthma in childrenSulphonylurea monotherapy for patients with type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusNon-acute percutaneous coronary intervention versus medical therapy in patients with ischaemic heart diseaseThe effects of high perioperative inspiratory oxygen fraction for adult surgical patientsVitamin D supplementation for prevention of cancer in adultsPulmonary perfusion versus no pulmonary perfusion during cardiopulmonary bypass for cardiac surgerySulphonylurea monotherapy for patients with type 2 diabetes mellitusInterventions to increase physical activity for people with congenital heart diseaseFibrinogen concentrate in bleeding patientsVitamin D supplementation for prevention of mortality in adultsOff-pump versus on-pump coronary artery bypass grafting for ischaemic heart diseaseAntibiotics for secondary prevention of coronary heart diseaseFlow-regulated versus differential pressure-regulated shunt valves for adult patients with normal pressure hydrocephalusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusProthrombin complex concentrate for perioperative reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients requiring acute surgical interventionFlow-regulated versus differential pressure-regulated shunt valves for adult patients with normal pressure hydrocephalusInhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adultsNon-incretin insulin secretagogues for patients with type 2 diabetes mellitusPositive end-expiratory pressure (PEEP) during anaesthesia for the prevention of mortality and postoperative pulmonary complicationsVitamin D supplementation for prevention of mortality in adultsThrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusionTransarterial (chemo)embolisation for unresectable hepatocellular carcinomaThe effects of high perioperative inspiratory oxygen fraction for adult surgical patientsUse versus avoidance of neuromuscular blocking agent for improving conditions during tracheal intubation or direct laryngoscopy in adults and adolescentsAerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusPentoxifylline for alcoholic hepatitisThrombelastography (TEG) or Thrombelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusionAerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusAntithrombin III for critically ill patientsVitamin D supplementation for prevention of cancer in adults
P50
Q21203731-7B5B3E94-F291-459B-B758-9A942AB64A12Q21203739-7E0C8008-1C0E-4FC9-B623-C7A0D6D78D13Q22241119-425547C1-083C-4934-83B1-22A5A065AD02Q22306541-47DAB44A-3E4D-4339-8962-9A1E8B7CD4B8Q24185986-008EB7D0-E7BB-4968-93EF-8221BAB25424Q24186159-2E3D1738-3FA8-4983-8AC3-AE31BE2230BDQ24186523-15D0B704-3AB3-4721-A3BE-816668A2A360Q24186648-CA9598E1-EA9E-4B9C-BEA1-5B3144D63ED0Q24186660-B74A538E-70AC-404F-A9DC-DFF170E7ADBFQ24186667-41EE7802-105E-4D7B-9271-BF6CB70F35D2Q24186673-AC9920D8-5A97-4D15-98C3-76D13DB1C841Q24187017-6A5DF8E6-D605-4089-9DE3-604683EEA70BQ24193850-E4F4F2C1-F829-4B55-B45C-8A9E08F79B58Q24194915-793809C9-7ACF-485D-9B29-78CE9AAA6D57Q24197884-37506BF8-4D85-47E9-A9BC-37766B35BD04Q24198254-93C35229-47B6-46A3-8071-2F95B095FEF1Q24200171-AA6E64E2-C468-459F-97B7-D1B76BD10E1CQ24201160-210117C3-F44D-4C88-AF94-DAAAB02CBBE4Q24201321-4509DB99-E665-464F-8EF5-E89DB6955497Q24201388-D229C90A-9C67-4391-B624-161B0BFD6F51Q24201435-27022F28-48E8-4273-AF12-9334F29B1682Q24202505-8858613F-5E52-442C-A8C6-1FFE5564D1ACQ24202561-6E08BD01-785B-4F7C-864C-F91F492B1F33Q24202666-C6787DD7-7C12-4A7B-94B4-6998B69F851BQ24234177-1B816F9B-9D65-4509-807A-171ACA3D5622Q24234574-D1F80C7C-F658-41E5-B927-B1F6971D73C3Q24235298-98F8821A-5FC6-4CB2-9357-A365EA6537BDQ24235390-1F4C889C-8500-4792-B2E4-023E77EE499FQ24235742-F3673E72-F4BE-4C23-A575-8D1DC1BCF0DAQ24235977-9C7029B7-F0BF-443A-BCB6-2392E3D4BF5CQ24236075-5BC1CE9E-3A38-4F01-93E8-C691F43A5C56Q24236134-32E64B34-4824-4EF5-97C5-878B1D41A23AQ24236378-DE18DEFA-D2DB-4AE0-8D0C-1735C5CE8524Q24236456-79758551-5ADA-4463-BD90-A754D3AD83DBQ24240223-65F385C4-0E95-40C3-9BC9-82CDE141A388Q24240465-B10A3F12-AF6B-4243-98E6-D3E7E01420FBQ24240827-3C181CB1-069E-414A-8310-EE3D6B4BF9BDQ24241529-F7A57464-51B7-4EF8-A08F-D0D89E558C51Q24242053-EE78FD6F-360A-44F3-A583-4AEEC9388352Q24242181-8B3E971B-B33F-41C9-9CC9-86A35E207A0F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jørn Wetterslev
@ast
Jørn Wetterslev
@en
Jørn Wetterslev
@es
Jørn Wetterslev
@fr
Jørn Wetterslev
@nl
Jørn Wetterslev
@sl
type
label
Jørn Wetterslev
@ast
Jørn Wetterslev
@en
Jørn Wetterslev
@es
Jørn Wetterslev
@fr
Jørn Wetterslev
@nl
Jørn Wetterslev
@sl
prefLabel
Jørn Wetterslev
@ast
Jørn Wetterslev
@en
Jørn Wetterslev
@es
Jørn Wetterslev
@fr
Jørn Wetterslev
@nl
Jørn Wetterslev
@sl
P106
P21
P31
P496
0000-0001-7778-1771
P569
2000-01-01T00:00:00Z